Key result
Adjusted cardio-ankle vascular index did not differ significantly between asymptomatic patients with heterozygous familial hypercholesterolemia and healthy controls (7.5 vs 7.7, p=0.061).
Why the study?
Is the cardio-ankle vascular index (CAVI) different in patients with heterozygous familial hypercholesterolemia compared to healthy controls?
Cross-Sectional (n=441)
No
Is the cardio-ankle vascular index (CAVI) different in patients with heterozygous familial hypercholesterolemia compared to healthy controls?
Absolute Event Rate: 7.5% vs 7.7%
p-value: p=0.061
In asymptomatic patients with heterozygous familial hypercholesterolemia on long-term lipid-lowering therapy, arterial stiffness measured by CAVI is comparable to that of healthy controls.
No takes yet. Share an insight, caveat, or question.
Supports effective stiffness mitigation by long-term therapy in asymptomatic HeFH; leaves open CAVI's prognostic utility in prospective FH studies.
Soška et al. (2012) conducted a cross-sectional in Heterozygous Familial Hypercholesterolemia (n=441). Heterozygous Familial Hypercholesterolemia vs. Healthy controls was evaluated on Age, sex, and BMI adjusted Cardio-Ankle Vascular Index (CAVI) (p=0.061). Adjusted cardio-ankle vascular index did not differ significantly between asymptomatic patients with heterozygous familial hypercholesterolemia and healthy controls (7.5 vs 7.7, p=0.061).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: